Metabolic syndrome in patients with schizophrenia independently from atypical antipsychotics intake;Syndrome métabolique chez les patients atteints de schizophrénie indépendamment de la prise d'antipsychotiques atypiques

Presse Medicale

Volumn 41, Issue 5, 2012, Pages

  Bou Khalil, Rami ^a,b  

^a Hopital Psychiatrique de la Croix   (Lebanon)

^b SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; MOOD STABILIZER;

ABDOMINAL OBESITY; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; MEDICAL CARE; METABOLIC SYNDROME X; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SEDENTARY LIFESTYLE; SMOKING HABIT; SOCIAL CLASS;

ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; SCHIZOPHRENIA;

EID: 84860472828     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.10.013     Document Type: Article

References (40)

1. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004, 65(suppl. 7):4-18.
2. Newcomer J.W. Metabolic syndrome and mental illness. Am J Manag Care 2007, 13(Suppl. 7):S170-S177.
3. De Hert M., Schreurs V., Vancampfort D., van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009, 8:15-22.
4. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497. Expert panel on detection, evaluation, treatment of high blood cholesterol in adults.
5. Lambert T.J.R. The medical care of people with psychosis. Med J Australia 2009, 190:171-172.
6. Zimmet P., Magliano D., Matsuzawa Y., Alberti G., Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005, 12(6):295-300.
7. Zimmerman U., Kraus T., Himmerich H., Skuld A., Pollmacher T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatric Res 2003, 37:193-220.
8. Kohen D. Diabetes mellitus and schizophrenia: historical perspective. Br J Psychiatry 2004, 184(Suppl. 47):s64-s66.
9. Andersohn F., Schade R., Suissa S., Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am J Psychiatry 2009, 166:591-598.
10. Gartlehner G., Thieda P., Hansen R.A., Gaynes B.N., Dveaugh- Geiss A., Krebs E.E., et al. Comparative risks for harms of second generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008, 31:851-865.
11. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003, 163:427-436.
12. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007, 68(Suppl. 4):8-13.
13. Sernyak M.J., Leslie D.L., Alarcon R.D., Losonczy M.F., Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002, 159:561-566.
14. Thakore J.H., Mann J.N., Vlahos I., Martin A., Reznek R. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 2002, 26:137-141.
15. Zhang Z.J., Yao Z.J., Liu W., Fang Q., Reynolds G.P. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004, 184:58-62.
16. Rosmond R. The glucocorticoid receptor gene and its association to metabolic syndrome. Obes Res 2002, 10:1078-1096.
17. Seckl J.R., Morton N.M., Chapman K.E., Walker B.R. Glucocorticoids and 11 beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004, 59:3593.
18. Elman I., Adler C.M., Malhotra A.K., Bir C., Pickar D., Breier A. Effect of acute metabolic stress on pituitaryadrenal axis activation in patients with schizophrenia. Am J Psychiatry 1998, 155:979-981.
19. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
20. Ryan M.C., Flanagan S., Kinsella U., Keeling F., Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 2004, 74:1999-2008.
21. Walker E., Mittal V., Tessner K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol 2008, 4:189-216.
22. Jones S.R., Fernyhough C. A new look at the neural diathesis-stress model of schizophrenia: the primacy of social evaluative and uncontrollable situations. Schizophr Bull 2007, 33:1171-1177.
23. Czobor P., Volavka J., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J., et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002, 22:244-251.
24. Corcoran C., Walker E., Huot R., Mittal V., Tessner K., Kestler L., et al. The stress cascade and schizophrenia: etiology and onset. Schizophr Bull 2003, 29(4):671-692.
25. Hammen C. Stress and depression. Ann Rev Clin Psychol 2005, 1:293-319.
26. Cohn T.A., Remington G., Zipursky R.B., Azad A., Connolly P., Wolever T.M. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 2006, 51:382-386.
27. van Nimwegen L.J., Storosum J.G., Blumer R.M., Allick G., Venema H.W., de Haan L., et al. Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 2008, 93:572-577.
28. Akanji A.O., Ohaeri J.U., Al-Shammri S.A., Fatania H.R. Associations of blood levels of insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-3 in schizophrenic Arab subjects. Clin Chem Lab Med 2007, 45:1229-1231.
29. Mukherjee S., Schnur D.B., Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989, 1(8636):495.
30. Mowry B.J., Nancarrow D.J. Molecular genetics of schizophrenia. Clin Exp Pharmacol Physiol 2001, 28(1-2):66-69.
31. van Tilburg J., van Haeften T.W., Pearson P., Wijmenga C. Defining the genetic contribution of type 2 diabetes mellitus. J Med Genet 2001, 38:569-578.
32. Rzhetsky A., Wajngurt D., Park N., Zheng T. Probing genetic overlap among complex human phenotypes. Proc Natl Acad Sci U S A 2007, 104(28):11694-11699.
33. Susser E.S., Lin S.P. Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945. Arch Gen Psychiatry 1992, 49(12):983-988.
34. Lin P.I., Shuldiner A.R. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res 2010, 123(2-3):234-243.
35. Li L., Wu R., Zhao J. Adiponectin gene +45T/G and +276G/T polymorphism and antipsychotic-induced weight gain. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2009, 34(8):693-696.
36. Templeman L.A., Reynolds G.P., Arranz B., San L. Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics 2005, 15(4):195-200.
37. Reynolds G.P., Zhang Z., Zhang X. Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. Am J Psychiatry 2003, 160(4):677-679.
38. Lane H.Y., Liu Y.C., Huang C.L., Chang Y.C., Wu P.L., Lu C.T., et al. Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 2006, 26(2):128-134.
39. Gorczynski P., Faulkner G. Exercise therapy for schizophrenia. Cochrane Database Syst Rev 2010, 5:CD004412.
40. Lambert T.J. The medical care of people with psychosis. Med J Aust 2009, 190(4):171-172.